Related Experiment Videos

Modulation of drug resistance in a daunorubicin resistant subline with oligonucleoside methylphosphonates

G Vasanthakumar1, N K Ahmed

  • 1Molecular Biology Section, Southern Research Institute, Birmingham, AL 35255-5305.

Cancer Communications
|January 1, 1989
PubMed

Insights

Researchers developed drug-resistant K562/III cells, finding mdr1 gene amplification. Oligonucleotides targeting the mdr1 gene inhibited P-glycoprotein synthesis and enhanced daunorubicin toxicity.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Human K562 erythroleukemia cells (K562/III) exhibit cross-resistance to multiple chemotherapy drugs.
  • This resistance is often associated with the multidrug resistance (MDR) phenotype.
  • The P-glycoprotein (P-gp) transporter, encoded by the mdr1 gene, is frequently implicated in MDR.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying daunorubicin resistance in K562/III cells.
  • To explore the role of the mdr1 gene and its transcript in conferring drug resistance.
  • To evaluate the potential of antisense oligonucleotides in overcoming MDR.

Main Methods:

  • Sequential selection of K562 cells for daunorubicin resistance.
  • Analysis of gene amplification and transcript levels of the mdr1 gene.
  • Treatment with non-ionic oligonucleoside methylphosphonates complementary to the mdr1 gene.
  • Assessment of P-glycoprotein synthesis and cellular toxicity of daunorubicin.

Main Results:

  • The K562/III subline demonstrated amplification of the mdr1 gene and its 4.5 kb transcript.
  • Non-ionic oligonucleoside methylphosphonates effectively inhibited P-glycoprotein synthesis.
  • These oligonucleotides partially restored daunorubicin sensitivity, increasing its toxicity.

Conclusions:

  • Amplification of the mdr1 gene is a key mechanism for daunorubicin resistance in K562/III cells.
  • Targeting the mdr1 gene with antisense oligonucleotides can overcome P-glycoprotein-mediated multidrug resistance.
  • Oligonucleotide-based strategies hold promise for enhancing chemotherapy efficacy in resistant cancers.

Related Concept Videos